VRDN: Viridian Therapeutics, Inc.
Performance
VRDN +10.02%
Watchlist
Select an item
Summary
VRDN at a glance
VRDN returned +10.02% over the past year and +9.69% a year over five years. Its worst drop in that year was -60.63%, smaller than 12% of stocks on Redstone, and its Sharpe ratio of 0.46 beats 48% of stocks on Redstone. It pays no dividends.
Current Drawdown
-10.63%
Rolling Volatility
70.30%
Actions
Metrics
Risk Indicators
Alpha21.52%
Beta1.14x
Sharpe0.46
Sortino0.65
Omega1.10
Calmar0.17
Martin0.94
Profile
About VRDN
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $3.4B
- Listed
- Jun 2014
- Employees
- 252
- Headquarters
- Waltham, MA
- Website
- viridiantherapeutics.com
Comparisons